PROCIZUMAB – a first-class drug candidate

Procizumab has an innovative mode of action relevant in acute diseases that are associated with massive cell death and uncontrolled release of intracellular DPP3 into the bloodstream. Translocated DPP3 remains active in the circulation where it cleaves bioactive peptides in an uncontrolled manner. Procizumab is able to block circulating DPP3, inhibiting bioactive peptide degradation in the bloodstream. This blockade results in stabilization of cardiovascular and renal function and reduction of short-term mortality.

Preclinical studies of Procizumab in animal models of cardiovascular failure showed impressive and instant efficacy. As an example, injection of PROCIZUMAB in rats with shock-induced cardiovascular failure led to an instant normalization of shortening fraction (see videos below).

Echocardiogram of rat heart with cardiovascular failure before PROCIZUMAB treatment

Echocardiogram of rat heart with cardiovascular failure after PROCIZUMAB treatment

PROCIZUMAB is a humanized monoclonal IgG1 antibody specifically binding circulating DPP3. It will be a first-in-class drug that targets and modulates DPP3 activity, an essential regulator of cardiovascular function.

  • High Preclinical Efficacy: In several preclinical cardiovascular failure models, PROCIZUMAB has shown to improve all clinically relevant endpoints in vivo. It normalizes ejection fraction and kidney function and reduces mortality.
  • GMP material development ongoing: A generic Good Manufacturing Practice (GMP) process is under development.
Targeted Therapy, Mode of Action Procizumab, DPP3, Pathway, 4TEEN4 Pharmaceuticals